In a career that spans a wide variety of unique professional environments, it seems like Kit Thorpe has seen it all.
A Guide to Accounting for an Efficient Life Sciences IPO: Streamlining Finance Processes When Going Public
Going public is a momentous occasion for any life sciences or biotechnology company, but the road to an IPO is littered with obstacles.
With the United States’ thriving IPO market, low volatility and large pool of investors, many U.
Kelly Provost is a leader in CFGI’s Life Sciences Capital Markets practice and has dedicated her career to supporting companies that are trying to cure diseases and save lives, making a difference in the lives of people across the world.
Melanie Kavanagh’s promotion to Partner has been an achievement in the making since the day she walked in the doors at CFGI in 2012.
CFGI’s Capital Markets team assisted Clene Nanomedicine (“Clene”) (NYSE: CLNN) with its SPAC merger with Tottenham Acquisition I Limited (“Tottenham”).